TECH OFFERS

With an ageing population and increased prevalence in diabetic onset, predisposition to chronic wounds including bed sores and diabetic foot ulcers poses a challenging situation for severe wound care management. Maggot Debridement Therapy (MDT), the oldest form of medicine has now re-emerged to be a promising treatment modality for chronic wounds. A biological tool, MDT serves as an alternative to surgical debridement. This involves the clinical use of sterile blowfly maggots to remove devitalized or necrotic tissues and reduce pathogen load. Topically applied to the chronic wound bed, this dressing facilitates better absorption, thereby providing an edge over existing interventions that lead to eventual amputations. Available in 2 forms, caged and uncaged, this live biodressing utilises natural biochemical processes of the blowfly larvae to conduct debridement that is comparable or better than conventional techniques in reducing critical wound healing time window. Uniquely designed to be used in both inpatient and outpatient settings, the biodressing enable surgical level debridement bedside, revolutionizing wound care with their precision and versatility. The technology provided include specifications on the operation of an ISO13485 laboratory, the Standard Operating Procedure (SOP) required for clinical usage of MDT as well as provision of training to the local clinicians on the use of MDT. The technology provider is looking to work with medical companies as well as government/medical institutions that are looking to have their patients under MDT to improve surgical outcomes, reduce the strain on the healthcare team and minimize costs associated with chronic wound care. Provision of SOP, Risk Assessment of an ISO13485 certified laboratory and insectary for the development of biodressing as a medical device globally.  Required documentation for local country registration, as per medical regulations. Provision of training for staff on the management of laboratory and insectary as per international standards (ISO13485). Comprehensive clinical documentation consisting of the placement, management, usage, and disposal of maggots. Techniques on the identification of local blowfly species, collection from habitat and method of laboratory sterilisation provided. Provision of essential QA techniques for the verification of biodressing to be safe and pathogen-free during both manufacture and transportation. Providing training to clinicians on the appropriate use and management of the biodressing. Clinical data obtained from the implementation of MDT shows promising patient outcomes and acceptance amongst the following: Patients deemed too high risk of surgery (i.e., poor blood supply) Diabetic patients with chronic wounds Non-healing wounds (i.e., ulcer injuries) Patients contraindicated for antibiotics With MDT, we are able to drive down amputation rates and clinically acquired infections to prepare the wound bed for accelerated healing and reduce time spent at the hospital. According to MarketsandMarkets, the global diabetes care devices market is poised to reach $4.3 Billion by 2025, growing at a CAGR of 16.2% from 2020 to 2025. With MDT, research studies have shown a threefold decrease in amputation rates. The effectiveness of MDT is evident through local clinical data that has demonstrated a limb salvage rate of 90.9% and a wound closure rate of 45.5% in a challenging patient population. With timely medical assistance rendered, risk of amputations is reduced, leading to a higher life expectancy and the element of quality being restored in their lives with confidence and independence.    Maggots exhibits accuracy and precision in the preparation of chronic wound beds, where it indiscriminately feeds on the necrotic tissues while leaving the healthy intact. Clinical studies on maggot therapy have shown that wounds are cleaned up to 18 times faster when compared to conventional methods that has increased rates of human error. Available in 2 forms: Free Range Larvae and Baggots (Maggots are enclosed within a sterile pouch with pores in the dressing to provide direct contact between larvae and wound bed).  Secretions from maggots have been reported to help reduce chronic inflammation and speed up the healing process. Cycling between MDT and Negative Pressure Wound Therapy (NPWT), the rate of wound healing is optimised, while reducing inflammatory exudate and promoting tissue granulation. MDT has been proven beneficial for high-risk patients with chronic wounds that does not respond well to surgical/conventional modes of wound debridement. This is backed up by statistics that shows a successful debridement after 4 weeks of MDT while necrotic tissues were observed even after 5 weeks of conventional therapies. Able to reach areas that are a challenge to access mechanically. Can be administered on patients outside the confinements of a healthcare facility. Maggot Debridement Therapy, Chronic wounds, Sterile medical-grade maggots, Efficacy, Cost Healthcare, Diagnostics, Medical Devices, Pharmaceuticals & Therapeutics

Lignocellulosic biomass side streams derived from the agri-food value chain such as agricultural residues, have the potential to be converted into high-value products, including biofuel, bio-composite construction materials, and sustainable packaging. Among the various conversion processes, pre-treatment plays a crucial role in maximizing the value of lignocellulosic biomass. The primary objective of pre-treatment is to address the complex and heterogeneous structure of the biomass by removing lignin, reducing biomass size, and increasing the surface area for hydrolysis. Unfortunately, current pre-treatment methods for lignocellulosic biomass are energy-intensive, costly, and produce inhibitory compounds that impact subsequent production stages. To overcome these challenges, this technology offers a catalytic oxidation pre-treatment process. This innovative approach operates under ambient or mild conditions, with a short reaction time, resulting in reduced energy consumption and treatment costs. The technology provider is seeking interested parties from the agricultural, biofuels, or biogas industry to license this catalytic oxidation pre-treatment process to enhance their operations and achieve a more sustainable and cost-effective production of valuable products from lignocellulosic biomass. The pre-treatment technology incorporates alkaline solutions, oxidizing agents, and synthetic catalysts to break down the recalcitrant structure of biomass and release soluble lignin. Mild operating conditions @ 1 atm pressure and 40-50oC Requires lower concentration & smaller volume of chemicals @ < 1% (w/v) Short reaction time (2-3 hours) Inhibitory compounds such as furfural and 5-HMF (Hydroxymethylfurfural) are removed in the process through oxidation This technology is mainly applied to pre-treat residual biomass but can be extended to the following applications: Lignin extraction Municipal sludge Palm Oil Mill Effluent (POME) treatment Recalcitrant wastewater treatment The biofuel industry is expected to grow at a CAGR of 7.9% by 2033. As companies look for more sustainable fuels for vehicles that cannot be easily electrised, biofuels will be the most suitable alternative to fossil fuels to cut down on carbon emissions. Valorization of agricultural waste that is rich in lignocellulosic cells as second-generation biofuels is also gaining prominence. Hence, this pre-treatment technology will be highly relevant in the coming years. Up to 90% energy savings @ ambient working conditions No inhibitory products produced High selectivity on aromatic compounds such as lignin increases the delignification effectiveness Lignocellulose, biomass, agrifood, Residual biomass pre-treatment, agriculture waste valorization, side stream Waste Management & Recycling, Waste-to-Energy, Food & Agriculture Waste Management, Sustainability, Circular Economy

With a projected market size of close to US$300M in 2025, printed thin film batteries are emerging as ideal candidates to power the next-generation wearables, medical and electronic devices. Unlike conventional batteries, printed thin-film batteries offers form-factor freedom, flexibility, providing power at sub-milimeter thickness and potentially cost effective to manufacture. Typically, zinc-manganese has been the chemistry of choice for printed batteries thanks to its low cost, high safety and ease of processing. Printed battery is manufactured by depositing conductive ink as a thin-film of paste onto a flexible polymer substrate (e.g., PET or heat-resistant polyimide films) by screen printing technique. Developed by an SME, the proprietary printed battery technology consists of layers of zinc anode, manganese dioxide cathode, electrolyte, separator, current collectors and sealing materials. The final battery is about 0.7 mm thick. While the energy capacities and size/shape could be customised depending on the use cases, the printed battery is best suited for applications at a power consumption of less than 50 mW. The technology owner may provide an initial assessment of the feasibility in using printed battery as a power source. If feasible, the technology owner may support in further brainstorming to optimise the power requirement and battery capacity for potential use cases. With a full grasp of the technical requirements, co-development activities including prototyping, battery integration with the final product (where applicable) will follow. For selected final products, the technology owner may serve as the original equipment manufacturer or original design manufacturer for the technology seeker. The standard non-rechargeable printed battery developed by the technology owner has the following technical specifications: Nominal voltage: 1.5 V to 3.0 V Initial capacities: 15 mAh @ 1 mA to 60 mAh @ 1 mA Initial internal resistance: ~20 Ω to ~90 Ω Maximum peak current: 25 mA for 5 ms Shelf life: minimum 2 years The outer dimensions, thickness and shape of battery as well as terminal size and location can be tailored according to the use cases: Customisation (area): 2 to 100 cm2 Customisation (capacity): up to 400 mAh Bending radius: the printed battery can be attached to a curved surface with a minimum radius of 35 mm. The thin film paper battery may be designed and customised to supply power to the following products and applications: Wireless sensor labels for temperature monitoring or asset tracking Wireless skin patches for monitoring vital signs Cosmetics patches and masks for skin care Smart wound healing dressings Intelligent packaging lighting, display and tracking New products that benefit from the thin and flexible form factor US$296M in 2025 and CAGR 24.7% from 2020-2025 (MarketsandMarkets, 2020) Customisable, flexible printed batteries for multiple applications. Printed battery, Flexible battery, Flexible electronics Energy, Battery & SuperCapacitor

Traditional methods of culturing organoids are labor-intensive, time-consuming, and limited in their ability to produce large quantities of organoids with consistent quality and characteristics. This technology enables the production of homogenized organoids of consistent quality. It utilizes specialized conditions to facilitate mass production and automate the cultivation of organoids derived from various tissues and organs, including the liver, kidney, lung, and brain. The IP addresses a need in the marketplace by providing a more efficient and cost-effective method of producing organoids. This technology reduces the time and cost of producing organoids while improving the reproducibility and scalability of the process. This can accelerate drug discovery and development, improve the accuracy of toxicology testing, enable the development of personalized medicine, and eventually replace the need for animal testing in the long-term vision of drug development. The technology provider will be producing the desired organoids as the end product with a further aim to enable a platform service for toxicity and efficacy testing when fully commercialized. The identity of the organoids will be validated by expression of relevant biomarkers. The end users of this technology are likely to be pharmaceutical companies, biotech firms, academic research institutions, and clinical laboratories. Overall, the technology has the potential to transform the way organoids are produced and used in the biomedical field. The technology owner is actively seeking for R&D collaboration to allow integration into existing protocols and testing with institutions, biotech companies and Contract Research Organizations (CROs). A bioink composition for organoids generation and characterisation Method for creating consistent cell droplets, culturing them in suspension, and sorting them by desired characteristics Cost-effective, leading to a 10x reduction in price Cryopreservation of organoids can be implemented for long-term storage and to ensure stable delivery This solution is intended to be a platform technology to be deployed in the biomedical industry, specifically in drug discovery on molecular drugs or gene therapies, toxicology testing, disease modeling, and personalized medicine, as well as CROs providing testing services and biotech firms developing early-stage drugs. The products that can be marketed based on this technology are organoid assays derived from various human tissues and organs, such as liver, kidney, lung, and brain. These organoids can be used for various applications, including: Testing drug toxicity and efficacy Investigating disease mechanisms and identifying drug targets Developing personalized therapies for patients The organoids market is projected to grow at a significant rate in the coming years, with an increasing demand for personalized medicine and improved drug discovery and toxicology testing methods. According to a report by MarketsandMarkets, the organoids market is expected to reach USD 1,642 million by 2025, growing at a CAGR of 20.4% from 2020 to 2025. The drug discovery outsourcing market was valued at USD 4.03 billion in 2020 and is also expected to grow at a compound annual growth rate (CAGR) of 7.8% from 2021 to 2028, according to a report by Grand View Research. The increasing demand for novel and effective drugs, the rising cost of in-house drug development, and the need to expedite drug development timelines are some of the key factors driving the growth of this market. Pharmaceutical and biotech companies, as well as academic research institutions, are among the key buyers of drug discovery outsourcing services. These companies outsource drug discovery services to Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs) to reduce costs and accelerate drug development timelines. The technology represents a significant improvement over the current state-of-the-art in organoid production. Currently, the most common methods for organoid production involve manual culturing, which is prone to variability and can be time-consuming and labor-intensive. Although some automation, such as the use of microfluidics and robotics, has been incorporated into organoid production, these methods are still limited in terms of organoid yield and quality. Our technology offers several advantages and differentiates itself from competitors in several ways: Scalability: One of the key advantages of this technology is its ability to scale up organoid production to an industrial level. The homogenization and suspension of organoids allow for efficient automation and mass production of organoids, reducing the time and cost of production. Standardization: The technology offers a more standardized and reproducible process for organoid production, reducing variability between batches and improving the accuracy of drug testing and development. Versatility: The technology can be applied to generate organoids from various organs and tissues, allowing researchers to study multiple disease models in a more comprehensive manner. This versatility allows for a wider range of applications and increases the potential market size. Cost-effectiveness: The streamlined process and scalability of the technology can lead to significant cost savings compared to other organoid production methods, making it more accessible to researchers and companies. Homogenized organoids, mass production, automation, drug discovery, toxicology testing, personalized medicine, reproducibility, scalability, transformative technology Healthcare, Pharmaceuticals & Therapeutics, Manufacturing, Additive Manufacturing, Life Sciences, Industrial Biotech Methods & Processes

Diabetes is a prevalent and growing health problem worldwide, affecting 1 in 10 people, with 90% of cases being type 2 diabetes. Congenital diabetes also affects 1 in 6 live births. In the next 20 years, diabetes is projected to increase by 46%. More than half a billion people are affected globally, 400,000 of them are in Singapore and if nothing is done by 2050, there will be one million diabetics patients in Singapore.   The company offers two technical solutions in form of a blended powder format: 1) Low Glycaemic Index (GI) and 2) Low Glycaemic Index (GI) with added protein.   The blend is plant-based, a source of protein, high in dietary fibre and replaces sugar from 20% to 100% in recipes across various food and beverage applications, it is versatile, high solubility, no alternation to original taste.   The solution is primarily targeted at Food Service sectors operators and manufacturers who seeks to penetrate the reduced sugar food & beverage market.  The technology consists of a proprietary blend (formulated by a renowned research institute based in Singapore) and consist of ingredients and composition that has clinically proven results of lowered GI. Affordable and cost effective compared to functional sugars No alteration to original taste of recipe Versatility of application due to its high solubility The applications include but are not limited to: Beverage Products (Bubble Tea, Ready-To-Drink, Pre-Packaged, Hot & Cold Beverages) Bakery Products (Cookies, Muffins, Pies, Tarts, Cakes, Brownies) Dairy (Milkshakes, Ice Creams, Gelato, Frozen Yogurt) Desserts (Asian & Western) The global reduced sugar food & beverage market size is at US$46.1bil, growing at CAGR of 9.53% in next 5 years, APAC is the fastest growing region, valued at US$12.9bil. It is a global movement to fight against diabetes through educational campaigns and government intervention. The Singapore Government decided to introduce mandatory nutrition labels and advertising prohibitions for Nutri-Grade beverages across all formats. The innovative solution offers immense versatility, catering to a broad spectrum of food items. Unlike the current state-of-the-art, which primarily focuses on baked goods and rice, the technology is not restricted to the same spectrum offered by competitors. The potential applications of the technology are limitless, offering a significant advantage over existing solutions. Furthermore, clinical trials have been conducted to validate the efficacy of the technology in food product sets them apart from the current state-of-the-art. In addition, the company possess the technological capabilities to demonstrate the effectiveness and efficacy of their solution across a broad range of food items. This ability to provide concrete evidence of their technology's efficacy offers a compelling advantage to customers looking to adopt innovative, effective, and reliable solutions to meet the demands of the growing diabetic and obese market. Low GI, Low Glycaemic Index, Low Glycaemic Load, Diabetics friendly, Low Glycemic Index, Obesity, Reduced sugar, Better for you, Keto friendly, Plant based, vegan, Healthier choice, HCS, Nutri grade, Halal certified Foods, Ingredients

Plywood is a preferred material used in furniture and home building for its durability since the Egyptian and Roman times. In 2019, the world consumed 165 million cm3 of plywood and was responsible for the creation of more than 3 billion tons of CO2. Applications for plywood are widespread including construction, home, retail, and office interior works and furnishings such as cabinetry, woodworking, renovations, and outfitting . Regulations and protectionism to slow down deforestation plus the tightening of sustainable forestry management lessen the supply of logging for plywood.  As global demand continues to be strong, the search for a viable replacement for plywood has become more pressing. More importantly, it is important to find a non-wood-based replacement with similar performance to plywood. Plywood is desirable because of its superior performance properties. Alternatives like medium-density boards (mdf) and particle boards are made from recycled wood waste. Unfortunately, plywood can only be made from virgin wood and there are no direct replacements for plywood currently. This technology leverages the global abundance of lignocellulosic fibre waste which is the discarded waste material after the harvesting and production of palm oil, rice, and wheat. The technology transforms these lignocellulosic fibre wastes into a direct replacement for conventional plywood.  This provides a sustainable, economically viable, and environmentally friendly solution to the continuing demand for plywood and the resolution to the growing lignocellulosic fiber waste problem in agri-food-based countries all over the world. The technology owner is open to various forms of collaboration including IP licensing, R&D collaboration, and test-bedding with different types of agrifood sidestreams. In the case of palm biomass waste, rice, and wheat straw waste, the technology is ready for commercialization. Produced material comparable to Grade A plywood in all performance parameters including modulus of rupture (MOR), modulus of elasticity (MOE), and water swelling Lower CAPEX & OPEX compared to producing conventional plywood Conversion process able to utilize standard commercial manufacturing equipment Activates the lignin within the agricultural biomass and transforms it into a 'natural superglue’ without commonly used formaldehyde-based binders Utilizes a series of hot presses under swinging and cyclical pressures and temperatures Construction Furniture Packaging Sports Equipment Automotive Industry Marine Industry Based on market research, the plywood industry is projected to experience significant growth from $54.79 billion in the current year to $85.26 billion by 2027, at a compound annual growth rate (CAGR) of 9.4%. With the increasing demand for sustainable materials and the valorization of agricultural waste, there is a potential opportunity for technology to emerge as a sustainable substitute for plywood in this expanding market. Sustainable solution as a direct replacement to plywood that reduces deforestation and recovers tremendous amounts of CO2 Non-added formaldehyde (NAF) Valorized plywood replacement comparable to Grade A plywood A credible global solution that contributes to reversing climate change Valorisation, agrifood, waste to worth, high value Waste Management & Recycling, Food & Agriculture Waste Management, Sustainability, Circular Economy

Smart Inhalers pose great potential in empowering disease management. Common difficulties faced by patients in the use of inhalers include inaccurate dosing, incorrect inhalation technique, insufficient deep inspiration flow rate and compliance. This technology aims to tackle the issue of over or underdosage delivery, device misuse and lack of monitoring or analytics found in current technologies. Using its proprietary precision dosing system, the device can accurately control dosages with an error rate of as low as 4% while enabling intelligent therapy monitoring and medical reporting for improved patient adherence and treatments. The device functions by breath-activated operation to prevent wastage, heat-free fine particle liquid nebulization for safer drug delivery and deeper lung deposition. It features a propellant-free compact (pocket-sized) smart inhaler with liquid drug cartridges designed to replace injections and modernize inhaled therapies using the lung as a platform for delivery, addressing the lack of pain-free, hassle-free, smart alternatives for various medications. Due to its proprietary atomizer that works on almost 90% of most liquid medication, it has significant potential to be scaled in various drug types and markets, such as insulin, antivirals, hormones, and smart intranasal delivery for neurological conditions.  The technology owner is actively seeking collaboration opportunities with commercialization partners, pharmaceutical, biotech, OEM, CRO companies, who can license it to bring it to market or integrate it into existing healthcare systems. This scalability makes the technology highly appealing to a wide range of potential partners and licensees including co-development for customization and R&D or joint venture.   Proprietary precision dosing system: Built-in circuitry that continuously monitors and controls consistent piezo's operation. Ensures accurate, stable, and quantifiable volume of liquids being atomized. Deep penetration and targeting: Patented technology engineers the piezo to stably operate around the optimal 2.5 microns for deep deposition into lungs. (Particles around 1 micron are exhaled because they are too light/small, particles above 4 microns are stuck in throat as they are too big/heavy). Programmable: Precision dosing can be controlled via device and phone by engineering a cut-off function so that device will not atomize when inhaled. Customization: Different formulations and multi-drug mixture in one pod or double cartridge delivery system. Flexibility: Options to deliver a wider range of medications, including micro-dosing (as low as 0.03ml/5secs) for more targeted and personalized treatment. Reducing the risk of adverse side effects and allowing for more effective treatment for sensitive patients. Heat-free and propellant-free nebulization: Does not affect medication degradation. Works with liquid medication (depends on viscosity of fluid). Breath-activated suction cap: Device does not have buttons. Intelligent therapy monitoring: The device automatically time stamps and captures each dose helping healthcare professionals track the progress of the therapy remotely. Liquid disposable cartridge system: Quick and hygienic medication replacement without the need for manual cleaning or maintenance of the inhaler. This reduces the risk of contamination or dosing errors. Patient-designed convenience: Non-removable rechargeable battery lasting up to one week before recharging. User friendly for patients to take their medication anytime and anywhere. Industries where this technology can be deployed include: Pharmaceutical and biotechnology companies Medical device manufacturers Healthcare providers and clinics Digital health platforms and telemedicine services Diabetes care Value added generic medicine Potential products based on this technology include: Broadening the arsenal of therapeutic options for the Health Care Providers New alternative to injections and current inhalation devices Smart intranasal delivery devices for neurological conditions and mental health treatments, increasing the potential for targeted drug delivery to the brain Integration with other health monitoring apps for better adherence and reporting (like continuous glucose monitors) Developing inhalable versions of pain-relief medications for patients who struggle with swallowing pills or require rapid onset of pain relief Smart inhalers for insulin delivery Faster and more efficient way to deliver antibiotics for respiratory infections, such as pneumonia or bronchitis, potentially reducing treatment duration and improving patient outcomes A more comfortable and less invasive method for administering vaccines, potentially increasing vaccination rates and improving public health Developing targeted inhalable chemotherapy or immunotherapy treatments for lung cancer or other respiratory-related malignancies, potentially reducing systemic side effects and increasing treatment efficacy The approximate market size for this smart inhaler technology can be substantial, given its potential applicability across various therapeutic areas. The global inhaler market was valued at around US$39.3 Billion in 2022 while the diabetes management market US$92.97 Billion. Considering the smart inhaler's ability to address both the pulmonary drug delivery and daily injection markets, the Total Available Market can be up to a US$1 Trillion adding up all the therapeutic areas. This proprietary smart inhaler technology represents a significant improvement over the current "State-of-the-Art" in drug delivery systems. Its unique value lies in its combination of precision dosing, versatility, and improved patient experience. Benefits for healthcare professionals and patients include: Ensuring accurate dose administration, driving therapy effectiveness Greater therapy monitoring and personalized care Differentiating drug offerings and broadening therapeutic options for healthcare providers Simplifying drug delivery, increasing patient satisfaction Intelligent therapy monitoring and medical reporting features leads to enhanced patient experience Health-economic benefits: Reducing waste and optimizing resource utilization Enhancing adherence, leading to better health outcomes and reduced healthcare costs Expanding the reach of insulin therapy to more people, addressing unmet needs Potential cost savings for payers Pricing flexibility that accounts for the benefits of the new application Benefits for partners: By maximizing drug portfolio potential, this technology allows pharmaceutical companies to diversify, differentiate, and defend against patent expiration, leading to improved patient outcomes and market growth Inhaled Drug Delivery, Medical Device, Remote Diagnostics, Patient-centric healthcare, Personalized medicine, Nebulization, Patent-protected technology, Alternative to injections, Chronic disease management, Digital health innovation Electronics, Sensors & Instrumentation, Healthcare, Medical Devices, Telehealth, Medical Software & Imaging, Pharmaceuticals & Therapeutics, Life Sciences, Industrial Biotech Methods & Processes

Pressure sensitive adhesives (PSAs) are viscous resins that are designed to adhere to various substrates under light pressure. Majority of commercially available PSAs are derived from non-renewable petroleum sources such as acrylics and silicones, providing the required bonding performance for either permanent or removable applications for use in labels and packaging. However, conventional PSAs present environmental concerns at their end of life, even when its substrate is biodegradable. The technology on offer is a patented bio-based, compostable PSAs comprising of 95% soy and other bio-derived materials that costs less than petroleum adhesives. These PSAs can bond to a variety of substrates (including paper and foams), contains no solvent or water, lowers CO2 emissions when compared to conventional PSA. It can be applied using standard application techniques (slot die or gravure systems) and upon curing will result in a light, cream coloured film. The technology owner is seeking for R&D collaborations and IP licensing opportunities with Singapore partners to manufacture/utilise the technology in packaging and non-structural applications. The technology is a soy-based, hot melt PSA that enables excellent adhesion to a variety of substrates. Some features of the technology include: Does not contain water or solvent Comparable adhesive performance to petroleum-based PSAs Net negative CO2 emissions - 0.79kg CO2 sequestered per 1 kg manufactured Costs 20% less than competing petroleum-based PSAs Home compostable (ASTM 6400/EN 13432) and industrial compostable (ASTM 5511) Applied using standard application techniques such as slot die and gravure systems Can be UV or thermal cured Can be designed to be removable or permanent for labels and tapes Potential applications include (but are not limited to): Packaging such as flexible and paper-based Tapes Labels Protective films Commercial applications that require compostable, bio-based alternatives to acrylic The pressure sensitive adhesives market is projected to grow from USD 13.2 billion in 2022 to USD 16.9 billion by 2027, at a CAGR of 5.1% between 2022 and 2027. With this technology, companies will be able to move away from fossil-based PSAs and achieve their environmental, social and governance goals to combat climate change. Use of renewable, bio-based raw materials that is compostable Cost-effective solution that meets the performance of conventional PSAs Helps corporations meet sustainability objectives by reducing carbon footprint The technology owner is seeking for R&D collaborations and IP licensing opportunities with Singapore partners to manufacture/utilise the technology in packaging and non-structural applications. adhesive, packaging, compostable, bio-based, environmentally friendly, sustainable, pressure sensitive, soy, bonding, tape, label, eco-friendly, films, paper, plastic packaging, circular economy, reduced carbon emissions Manufacturing, Chemical Processes, Chemicals, Organic, Bio-based, Sustainability, Circular Economy

Recently, the rising adoption of Internet of Things (IoT) devices and portable electronics has made electronic waste (e-waste) pollution worse, especially when small and low-power IoT devices are single-use only. As such, low-cost and environmentally friendly power sources are in high demand. The technology owner has developed an eco-friendly liquid-activated primary battery for single-use and disposable electronic devices. The battery can be activated by any aqueous liquid and is highly customisable to specific requirements (i.e., shape, size, voltage, power) of each application. This thin and flexible battery can be easily integrated into IoT devices, smart sensors, and medical devices, providing a sustainable energy solution for low-power and single-use applications. The technology owner is keen to do R&D collaboration and IP licensing to industrial partners who intend to use liquid-activated batteries to power the devices. The technology is a single-use and non-rechargeable battery that can be instantly activated by any aqueous liquid (e.g., water, fruit juice, soft drink, etc.) as well as all types of body fluids (e.g., blood, saliva, urine, sweat, bile, etc.). The features of this technology are: Customisable shape, size, and power (1.5 to 6.0 V at 4 to 50 mW) Ultra-thin and flexible (<1 mm in thickness) Lightweight (when dry) High energy density (less than 5 mm2 for low-power application: 1.5 V, 2 mAh) Indefinite pre-activation shelf-life (no self-discharge) Non-toxic and biocompatible (safe for human beings) Environmentally friendly (no disposal pollution) This inherently safe and non-toxic battery can be widely applied in MedTech applications, disposable IoT, smart sensors, and low-power electronics. The potential applications include but are not limited to: Medical devices: digital pills, ingestible sensors, smart bandages, wearable biosensors, in-vitro diagnostics (IVDs), body fluid testing, etc. Disposable IoT: Bluetooth Low Energy (BLE) chips, microprocessors, wireless sensors (pH, temperature, humidity), micromotors, LEDs, heaters, etc. Other low-power electronics: smart labels, electronic skin patches, cold chain monitoring, smart packaging, etc. The technology offers the following unique features: Highly customisable for different applications Thin and flexible (adaptable to various designs) Long shelf-life (can be sealed for a very long time) Biocompatible (can be safely consumed) Environmentally friendly and non-toxic The technology owner is keen to do R&D collaboration and IP licensing to industrial partners who intend to use liquid-activated batteries to power the devices.  Primary Battery, Environmentally Friendly, Non-Toxic, MedTech, Disposable IoT Energy, Battery & SuperCapacitor, Healthcare, Medical Devices, Infocomm, Internet of Things